Seeking Funds For Phase III Antibiotic, Paratek Files For IPO
This article was originally published in The Pink Sheet Daily
The Boston-based drug developer believes it has resolved the regulatory issues that led to the dissolution of a partnership with Novartis around the drug omadacycline.
You may also be interested in...
Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.